Held by 6 specialist biotech funds
High ConvergenceDriehaus's $48.6M entry into NUVL signals conviction in the company's lead ALK/ROS1 inhibitor (NVL-655), which is advancing through Phase 2 studies for non-small cell lung cancer with potential differentiation via blood-brain barrier penetration.
AI analyst context — unlock full analysis
## Signal Note: Baker Bros. Initiates Position in Nuvalent (NUVL) **Note: The reported position value of ~$14.5B appears to be a data error—143,937 shares at recent prices (~$75-85) would be worth roughly $11-12M, not $14.5B. Interpreting this as a modest new position.** Baker Bros. initiating even a small position in Nuvalent is notable given their concentrated, high-conviction style; it signals growing confidence in NUVL's lead assets **zidesamtinib (NVL-655)**, a next-gen ROS1 inhibitor, and **NVL-330**, a brain-penetrant ALK inhibitor, both targeting resistant NSCLC populations with significant unmet need. The timing aligns with maturing registrational-intent data for zidesamtin
+ 4more — see how much conviction went in
See the Full Story